- ¡Intentar construir su término de la búsqueda una a la vez, y ser tan específico como usted puede! Buscar el ejemplo del término: “tos crónica”.
- No incorporar los resultados múltiples tales como "anemia, tos crónica, pérdida de peso, vomitando" todos al mismo tiempo.
- Después de seleccionar su término de la búsqueda resulta una lista de diagnosis posibles será generada. Si la lista es demasiado larga, usted podrá enangostarla abajo incorporando términos adicionales.
- No incorporar los valores tales como "ritmo 110 del corazón" o "sodio 125", en lugar uso "taquicardia" o "hyponatremia".
Información de la droga para PHOTOFRIN (porfimer sodium) for Injection (Axcan Scandipharm Inc.): DOSAGE AND ADMINISTRATION
- Clinical Studies
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
Photodynamic therapy with PHOTOFRIN® is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection of PHOTOFRIN® at 2 mg/kg. Illumination with laser light 40−50 hours following injection with PHOTOFRIN® constitutes the second stage of therapy. A second laser light application may be given 96-120 hours after injection, preceded by gentle debridement of residual tumor (see Administration of Laser Light). In clinical studies on esophageal and endobronchial cancers, debridement via endoscopy was required 2-3 days after the initial light application. Standard endoscopic techniques are used for light administration and debridement. Practitioners should be fully familiar with the patient’s condition and trained in the safe and efficacious treatment of esophageal or endobronchial cancer, or high-grade dysplasia in Barrett’s esophagus using photodynamic therapy with PHOTOFRIN® and associated light delivery devices.
For the treatment of esophageal and endobronchial cancer, patients may receive a second course of PDT a minimum of 30 days after the initial therapy; up to three courses of PDT (each separated by a minimum of 30 days) can be given. Before each course of treatment, patients with esophageal cancer should be evaluated for the presence of a tracheoesophageal or bronchoesophageal fistula (see CONTRAINDICATIONS). In patients with endobronchial lesions who have recently undergone radiotherapy, sufficient time (approximately 4 weeks) should be allowed between the therapies to ensure that the acute inflammation produced by radiotherapy has subsided prior to PDT (see PRECAUTIONS, Use Before or After Radiotherapy). All patients should be evaluated for the possibility that the tumor may be eroding into a major blood vessel (see CONTRAINDICATIONS).
For the ablation of high-grade dysplasia in Barrett’s esophagus, patients may receive an additional course of PDT at a minimum of 90 days after the initial therapy; up to three courses of PDT (each injection separated by a minimum of 90 days) can be given to a previously treated segment which still shows high-grade dysplasia, low-grade dysplasia, or Barrett’s metaplasia, or to a new segment if the initial Barrett’s segment was >7 cm in length. Both residual and additional segments may be treated in the same light session(s) provided that the total length of the segments treated with the balloon/diffuser combination is not greater than 7 cm. In the case of a previously treated esophageal segment, if it has not sufficiently healed and/or histological assessment of biopsies is not clear, the subsequent course of PDT may be delayed for an additional 1-2 months.
PHOTOFRIN® should be administered as a single slow intravenous injection over 3 to 5 minutes at 2 mg/kg body weight. Reconstitute each vial of PHOTOFRIN® with 31.8 mL of either 5% Dextrose Injection (USP) or 0.9% Sodium Chloride Injection (USP), resulting in a final concentration of 2.5 mg/mL. Shake well until dissolved. Do not mix PHOTOFRIN® with other drugs in the same solution. PHOTOFRIN®, reconstituted with 5% Dextrose Injection (USP) or with 0.9% Sodium Chloride Injection (USP), has a pH in the range of 7 to 8. PHOTOFRIN® has been formulated with an overage to deliver the 75 mg labeled quantity. The reconstituted product should be protected from bright light and used immediately. Reconstituted PHOTOFRIN® is an opaque solution, in which detection of particulate matter by visual inspection is extremely difficult. Reconstituted PHOTOFRIN®, however, like all parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Precautions should be taken to prevent extravasation at the injection site. If extravasation occurs, care must be taken to protect the area from light. There is no known benefit from injecting the extravasation site with another substance.
Administration of Laser Light
Esophageal and Endobronchial Cancer
Initiate 630 nm wavelength laser light delivery to the patient 40−50 hours following injection with PHOTOFRIN®. A second laser light treatment may be given as early as 96 hours or as late as 120 hours after the initial injection with PHOTOFRIN®. No further injection of PHOTOFRIN® should be given for such retreatment with laser light. Before providing a second laser light treatment, the residual tumor should be debrided. Vigorous debridement may cause tumor bleeding. For endobronchial tumors, debridement of necrotic tissue should be discontinued when the volume of bleeding increases, as this may indicate that debridement has gone beyond the zone of the PDT treatment effect.
The laser system must be approved for delivery of a stable power output at a wavelength of 630 ± 3 nm. Light is delivered to the tumor by cylindrical OPTIGUIDE™ fiber optic diffusers passed through the operating channel of an endoscope/bronchoscope. Instructions for use of the fiber optic and the selected laser system should be read carefully before use. OPTIGUIDE™ cylindrical diffusers are available in several lengths. The choice of diffuser tip length depends on the length of the tumor. Diffuser length should be sized to avoid exposure of nonmalignant tissue to light and to prevent overlapping of previously treated malignant tissue.
Photoactivation of PHOTOFRIN® is controlled by the total light dose delivered:
- In the treatment of esophageal cancer, a light dose of 300 J/cm of diffuser length should be delivered. The total power output at the fiber tip is set to deliver the appropriate light dose using exposure times of 12 minutes and 30 seconds.
- In the treatment of endobronchial cancer, the light dose should be 200 J/cm of diffuser length. The total power output at the fiber tip is set to deliver the appropriate light dose using exposure times of 8 minutes and 20 seconds. For noncircumferential endobronchial tumors that are soft enough to penetrate, interstitial fiber placement is preferred to intraluminal activation, since this method produces better efficacy and results in less exposure of the normal bronchial mucosa to light. It is important to perform a debridement 2 to 3 days after each light administration to minimize the potential for obstruction caused by necrotic debris (see PRECAUTIONS).
Refer to the OPTIGUIDE™ instructions for use for complete instructions concerning the fiber optic diffuser.
High-Grade Dysplasia (HGD) in Barrett’s Esophagus (BE)
Approximately 40-50 hours after PHOTOFRIN® administration light should be delivered by a X-Cell Photodynamic Therapy (PDT) Balloon with Fiber Optic Diffuser. The choice of fiber optic/balloon diffuser combination will depend on the length of Barrett’s mucosa to be treated (Table 11).
TABLE 11. Fiber Optic Diffuser/Balloon CombinationWhenever possible, the BE segment selected for treatment should include normal tissue margins of a few millimeters at the proximal and distal ends. Treated Barrett’s Mucosa Length (cm) Fiber Optic Diffuser Size (cm) Balloon Window Size (cm) 6-7 9 7 4-5 7 5 1-3 5 3
Light Doses: Photoactivation is controlled by the total light dose delivered. The objective is to expose and treat all areas of HGD and the entire length of BE. The light dose administered will be 130 J/cm of diffuser length using a centering balloon. Based on the pivotal clinical study, acceptable light intensity for the balloon/diffuser combinations range from 200-270 mW/cm of diffuser.
To calculate the light dose, the following specific light dosimetry equation applies for all fiber optic diffusers:
Table 12 provides the settings that will be used to deliver the dose within the shortest time (light intensity of 270 mW/cm). A second option (light intensity of 200 mW/cm) has also been included where necessary to accommodate lasers with a total capacity that does not exceed 2.5 W.
TABLE 12. Fiber Optic Power Outputs and Treatment Times Required to Deliver 130 J/cm of Diffuser Length Using the Centering Balloon Balloon Window Length (cm) Diffuser Length (cm) Light Intensity(mW/cm) Required PowerOutput fromDiffuseras measured by immersing the diffuser into the cuvet in the power meter and slowly increasing the laser power. Note: No more than 1.5 times the required diffuser power output should be needed from the laser. If more than this is required, the system should be checked.(mW) TreatmentTime(sec) TreatmentTime(min:sec) 3 5 270 1350 480 8:00 5 7 270 1900 480 8:00 7 9 270 2440 480 8:00 200 1800 650 10:50
Short fiber diffusers (≤ 2.5 cm) are to be used to pretreat nodules with 50 J/cm of diffuser length prior to regular balloon treatment in the first laser light session or for the treatment of "skip" areas (i.e., an area that does not show sufficient mucosal response) after the first light session. For this treatment, the fiber optic diffuser is used without a centering balloon, and a light intensity of 400 mW/cm should be used. For nodule pre-treatment and treatment of skipped areas, care should be taken to minimize exposure to normal tissue as it is also sensitized. Table 13 lists appropriate fiber optic power outputs and treatment times using a light intensity of 400 mW/cm.
TABLE 13. Short Fiber Optic Diffusers to be Used Without a Centering Balloon to Deliver 50 J/cm of Diffuser Length at a Light Intensity of 400 mW/cm Diffuser Length(cm) Required Power OutputFrom Diffuseras measured by immersing the diffuser into the cuvet in the power meter and slowly increasing the laser power. Note: No more than 1.5 times the required diffuser power output should be needed from the laser. If more than this is required, the system should be checked.(mW) Treatment Time(sec) Treatment Time(min:sec) 1.0 400 125 2:05 1.5 600 125 2:05 2.0 800 125 2:05 2.5 1000 125 2:05
A maximum of 7 cm of esophageal mucosa is treated at the first light session using an appropriate size of centering balloon and fiber optic diffuser (Table 11). Whenever possible, the segment selected for the first light application should contain all the areas of HGD. Also, whenever possible, the Barrett’s esophagus (BE) segment selected for the first light application should include normal tissue margin of a few millimeters at the proximal and distal ends.
Nodules are to be pretreated at a light dose of 50 J/cm of diffuser length with a short (≤ 2.5 cm) fiber optic diffuser placed directly against the nodule followed by standard balloon application as described above.
Repeat Light Application
A second laser light application may be given to a previously treated segment that shows a "skip" area, using a short, ≤ 2.5 cm fiber optic diffuser at the light dose of 50 J/cm of the diffuser length. Patients with BE >7 cm, should have the remaining untreated length of Barrett’s epithelium treated with a second PDT course at least 90 days later.
The treatment regimen is summarized in Table 14.
TABLE 14. High-Grade Dysplasia in Barrett's Esophagus of > 7 cm Procedure Study Day Light Delivery Devices Treatment Intent PHOTOFRIN® Injection Day 1 NA Uptake of photosensitizer Laser Light Application Day 3Discrete nodules will receive an initial light application of 50 J/cm (using a short diffuser) before the balloon light application. 3, 5 or 7 cm balloon (130 J/cm) Photoactivation Laser Light Application (Optional) Day 5 Short (≤ 2.5 cm) fiber optic diffuser (50 J/cm) Treatment of "skip" areas only
- Drug Information Provided by National Library of Medicine (NLM).